Immunophenotyping in Ocrelizumab-Treated Relapsing-Remitting MS Patients
In a study of 51 relapsing-remitting MS patients treated with ocrelizumab over four years, post-infusion lymphocyte counts returned to normal after an initial drop. There were also sawtooth patterns in total white blood cells and significant cyclic changes in monocyte counts, with an increase in the CD4+/CD8+ T cell ratio indicating elevated CD4+ T cells.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
These findings reveal dynamic changes in immune cell populations following ocrelizumab treatment, which may inform future research on immune modulation in MS.
What this does not prove
Details of immune dynamics after ocrelizumab treatment are limited and require further confirmation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 51 · number of relapsing-remitting MS patients
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- CD20-positive B lymphocytes
- Pathway
- Not reported
- Population
- relapsing-remitting MS patients
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceOcrelizumab-Induced Leukocyte Subpopulations Dynamics in Multiple Sclerosis. ↗DOI: 10.3390/ph19101514
Supporting passages (10)
sample size51
sample size basisMethods: In an observational, retrospective, and prospective real-world study, we studied 51 relapsing-remitting MS ocrelizumab-treated patients who underwent flow cytometric immunophenotyping before and after each infusion and at three-month intervals, up to the eighth (4 years), for a total of 408 cycles.
publication date2026-09-23
interventionocrelizumab
follow up4 years
findingsResults: After an initial decrease, post-infusion lymphocyte count returned to normal, while total white blood cells showed a sawtooth pattern driven by post-infusion increases.
biological targetsCD20-positive B lymphocytes
populationMethods: In an observational, retrospective, and prospective real-world study, we studied 51 relapsing-remitting MS ocrelizumab-treated patients who underwent flow cytometric immunophenotyping before and after each infusion and at three-month intervals, up to the eighth (4 years), for a total of 408 cycles.
limitationsTitle: Ocrelizumab-Induced Leukocyte Subpopulations Dynamics in Multiple Sclerosis.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.